Mission
SEE STATEMENT ON SCHEDULE O
Public Charity
FUND FOR OPHTHALMIC KNOWLEDGE INC C/O DAVID H ABRAMSON MD
FUND FOR OPHTHALMIC KNOWLEDGE INC C/O DAVID H ABRAMSON MD is a Public Charity headquartered in NEW YORK, NY. Financial data from the 2024 filing: $70K revenue, $136K expenses, $777K total assets. IRS filings disclose 9 grants awarded by this foundation, totaling roughly $1.2M.
EIN: 134171637
NEW YORK, NY
Fund Raising & Fund Distribution
NTEE: A12
Latest filing: 2024
Total Revenue$70K
Total Expenses$136K
Total Assets$777K
Grants Given9
Grant Total$1.2M
Filing Years2020–2024
Where $100 goes at Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md
How Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md divides every $100 it spends, from its own Form 990 filings, averaged across 8 years.
$95
Programs
the work itself
$5
Management
running the organization
$0
Fundraising
none reported
No fundraising costs are reported. That often means fundraising runs through a separate affiliated organization that files its own return.
Inside the $95 for programs
$41
Memorial sloan-kettering cancer center ("mskcc") ($56,128)
$39
Meetings and educational support ($53,006)
$14
Fundacion natali dafne flexer ($19,000)
Plus 1 more program. Cost per person served and the full program breakdown are on the full profile.
Source: Form 990 filings with the IRS, latest fiscal year 2024. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.
Sample Grants Given
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
$56,128
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
$198,692
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
$161,184
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
$56,184
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
$157,056
Showing up to 5 of 9 total records — full history available with membership.
Officers & Directors
DIRECTOR
Allan Abramson Md
DIRECTOR & PRESIDENT
David H Abramson Md
DIRECTOR & VP & TREASURER
Hilary Cruz-Abrams Bamphrn
DIRECTOR
Joseph Gold Md
DIRECTOR
Nicholas Grumbach Md
DIRECTOR
Robin Cruz-Abrams
Officer compensation and complete director data available with membership.
Top Grant Purposes
Financial Trends
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $70K | $136K | $777K |
| 2023 | $52K | $253K | $815K |
| 2022 | $105K | $255K | $966K |
| 2021 | $183K | $140K | $1.3M |
| 2020 | $74K | $197K | $1.2M |
Between 2020 and 2024, reported annual revenue declined from $74K to $70K (-6%), with total assets most recently reported at $777K.
Interactive year-over-year charts and full filing details available with membership.
Grant Geography
Grants from this foundation were reported to recipients in NY.
NY
Full geographic grant map with state-by-state breakdown available with membership.